α-Glucosidase Inhibitor Isolated from Blechum pyramidatum by Cherigo, Lilia & Martínez-Luis, Sergio
  
α-Glucosidase Inhibitor Isolated from Blechum pyramidatum 
 
Lilia Cherigoa and Sergio Martínez-Luisb,* 
 aDepartamento de Química Orgánica, Facultad de Ciencias Exactas y Tecnología, Universidad de Panamá,  
P.O. Box 3366, Panamá, República de Panamá 
 bCentro de Biodiversidad y Descubrimiento de Drogas, Instituto de Investigaciones Científicas y Servicios  
de Alta Tecnología (INDICASAT AIP), Edificio 219, Ciudad del Saber, Apartado 0843-01103, Panamá,  
República de Panamá 
 
smartinez@indicasat.org.pa 
 
 
Received: January 25th, 2018; Accepted: February 28th, 2018 
 
 
  
Blechum pyramidatum (Lam.) Urb. is a species of extensive medicinal use in the American continent. In fact, antidiabetic and anticancer preparations from this 
plant have been patented in Mexico, even though their active constituents are not yet known. It was recently discovered that B. pyramidatum inhibits the action 
of the -glucosidase enzyme, thereby corroborating the antidiabetic properties attributed to this plant. The primary purpose of this study was to identify and 
characterize the -glucosidase inhibitors from this species. Bioassay-guided fractionation of a crude extract of B. pyramidatum led to the isolation of a main -
glucosidase inhibitor, Palmitic acid (IC50 237.5). This compound was identified by both spectroscopic and spectrometric analysis. Its inhibitory activity was 
similar to that of the antidiabetic drug acarbose (IC50 241.6 µM), which was used as a positive control in our bioassay. Kinetic analysis established that 
palmitic acid acted as a competitive inhibitor. Docking analysis predicted that this compound binds to the same site as acarbose does in the human intestinal 
α‑glucosidase (PDB: 3TOP). The presence of palmitic acid in B. pyramidatum and its potent inhibitory activity against α‑glucosidase enzyme provides solid 
evidence to support the antidiabetic use of this plant in traditional medicine. 
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Medicinal plants have been systematically used since ancient times, 
especially in countries where significant ancestral cultures 
flourished [1]. Despite today’s technological advances, medicinal 
plants continue to be a widely used resource to prevent and treat 
human diseases. Recently, the World Health Organization estimated 
that approximately three-quarters of the world’s population trust 
and utilize plants for their health care needs [2]. Faced with this 
panorama, scientists from all over the world must continue to 
generate better information to develop recommendations for 
effective and safe uses of many medicinal plants. 
 
Blechum pyramidatum (Lam.) Urb. is a species of wide medicinal 
use in different countries of the American continent. Cooking of the 
leaves is prescribed to treat skin problems [3]. A decoction of this 
plant can be administered as a diuretic [4] and as an antiemetic [5]. 
In some places, this plant is applied to treat snakebites [6]. In 
Mexico, the antidiabetic and anticancer uses of this plant have been 
patented, although the active compounds have never been isolated 
nor identified [7]. Therefore, there is an urgent need to identify the 
active components of this plant to guarantee its quality and safe use. 
In a preliminary study, we detected that the organic extract from 
this plant showed significant inhibitory activity against the α-
glucosidase enzyme, although it was not possible for us to fully 
identify the component(s) responsible for that activity [8]. The latter 
was partly due to the presence of large amounts of chlorophyll and 
other related compounds, which interfered with the bioactivity 
results we obtained in the initial extraction of this plant. Still, 
obtained results suggests that inhibition of -glucosidase enzyme is 
part of antidiabetic mechanisms from this plant. 
 
It is important to point out that conventional bioassays performed to 
detect -glucosidase activity typically quantify the enzymatic 
activity by measuring the absorbance of the reaction mixture at 400 
nm [9a-c]. Chlorophyll and related compounds also exhibit intense 
absorption peaks at this same wavelength. Therefore, the removal of 
these types of compounds prior to chemical studies is essential to 
obtain more accurate results in detecting -glucosidase bioactivity. 
For this reason, we proceeded with the removal of chlorophyll and 
related compounds from the initial crude extract by using activated 
carbon to avoid interferences in the enzymatic readings. 
 
The aerial parts of B. pyramidatum were macerated with a mixture 
of CHCl3-MeOH (1:1). Subsequently, this mixture was blended with activated carbon, which was filtered and concentrated to obtain 
the crude extract. This extract inhibited 69.4 % of the -glucosidase 
activity at a final concentration of 6.25 mg/mL. Afterward, the 
organic extract was dissolved in a hydro- methanol mixture (20:80) 
and successively partitioned by two solvents, hexane and ethyl 
acetate, to obtain three major fractions with increasing polarity. Of 
these three fractions, only the hexane fraction showed promising 
activity (80.1 % of enzyme inhibition at 6.25 mg/mL). Bioassay-
guided fractionation of the hexane fraction allowed the isolation of 
palmitic acid (compound 1), as the main active compound from B. 
pyramidatum. This compound was identified by spectroscopic 
analyses including ESI-HR-MS and NMR (1H, 13C, DEPT 135, 
DEPT 90, COSY, NOESY, HMBC and HMQC) [8, 10].  
 
Compound 1 inhibited the α-glucosidase enzyme in a concentration-
dependent manner with an IC50 value of 237.5 µM therefore showing similar potency to acarbose (positive control, IC50 241.6 
µM). During -glucosidase evaluations, we initially found that 
palmitic acid only showed moderate activity, which did not 
correlate with the activity detected in the hexane fraction through 
which this compound was isolated. This fact allowed us to 
recognize that palmitic acid had poor solubility in DMSO. There 
have been previous reports about -glucosidase inhibition by fatty 
acids, including palmitic and oleic acids, with DMSO being 
regularly used to solubilize samples as part of standard protocols to 
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detect bioactivity [11a-c]. Our evidence suggested that a re-
evaluation of the inhibition of the α-glucosidase enzyme by palmitic 
acid in other solvents was necessary to both determine whether 
there was an effect by the reduced solubility of palmitic acid in 
DMSO and to compare our findings to previously reported 
enzymatic activity. To find a solvent which would allow us to get 
more reliable results for palmitic acid activity - and, in general, for 
low polar compounds - we proceeded to evaluate the inhibition of 
-glucosidase by some common solvents in different quantities, 
including ethanol, methanol, propanol, and isopropanol. Through 
these tests, we detected that ethanol in small volumes only slightly 
decreased the α-glucosidase activity and that palmitic acid was 
solubilized better than with DMSO.This finding allowed us to 
obtain more real inhibition results for low polarity compounds. 
 
We proceeded to evaluate the activity of palmitic acid using ethanol 
to compare to the results we obtained with DMSO. We also 
assessed oleic acid since this compound has similar solubility 
properties to those of palmitic acid, and we also re-evaluated the 
positive control, acarbose (IC50 217.7 µM in DMSO). As a result, oleic acid showed potent α-glucosidase inhibitory activity (IC50 38.9 µM), even better than palmitic acid, and acarbose showed similar 
potency to that displayed using DMSO (IC50 241.6 µM in ethanol). 
This evidence suggests that reported data about -glucosidase 
inhibition by certain low polar compounds could be inaccurate due 
to their poor solubility DMSO which is used in most standard 
protocols.  
 
To obtain further evidence of the nature of the interaction of 
palmitic (1) and oleic acids (2) with α-glucosidase, we carried out 
kinetic analyses. Lineweaver–Burk plots [12a] were constructed 
using different concentrations of substrate and fatty acids 1–2 
(Figure 1). The results in Figure 2 and Figure 3 indicated that 
compounds 1–2 showed typical reversible competitive plots, with 
series of lines having the same y-intercept as the enzyme without 
inhibitors. These results suggested that compounds 1–2 bind to α-
glucosidase or to the substrate-enzyme complex. Acarbose also 
behaved as a competitive inhibitor [12a]. These results show that 
both fatty acids are potent competitive inhibitors of the α-
glucosidase enzyme.  
 
 
 
 
 
 
 
Figure 1: (1) Palmitic acid and (2) Oleic acid. 
 
Taking into consideration the results of the kinetic analysis 
performed, we conducted a molecular docking study to evaluate the 
putative binding mode of fatty acids 1–2 into the human intestinal 
α-glucosidase (PDB: 3TOP). Results indicate that fatty acids bind 
mainly through hydrophobic interactions. Figure 4 shows the 
superposition of docking poses of compounds 1–2 and acarbose in 
the binding site. It is interesting to note that despite the analyzed 
fatty acids being mainly hydrophobic they bind to the same site as 
acarbose, which is a more polar compound compared to fatty acids 
1–2. As expected, acarbose interacts with the binding site through 
many hydrogen bonds (Figure 5a) and compounds 1–2 interact 
mainly via hydrophobic interactions (Figure 5b). However, palmitic 
acid interacts with Asp 1526 and Arg 1582 through the formation of 
hydrogen bonds while oleic acid weakly interacts with Lys 1460 by 
the formation of hydrogen bonds with hydroxyl groups (Figures 6). 
Finally, in the results of the docking analysis, it is clearly observed 
that the oleic acid pose fits better than the  palmitic acid  pose in the  
 
Figure 2: Lineweaver–Burk plot of -glucosidase inhibition at different concentrations 
of substrate and palmitic acid.   
 Figure 3: Lineweaver–Burk plot of -glucosidase inhibition at different 
concentrations of substrate and oleic acid.   
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Superposition of docking poses of compounds 1(in green), 2 (in blue) and 
acarbose (in red).  
 
-glucosidase receptor site. This finding suggests that the three-
dimensional arrangement due to the presence of the double bond is 
responsible for the better activity displayed by oleic acid. 
 
In summary, palmitic acid was isolated from the B. pyramidatum 
active fraction against -glucosidase. Even though this compound 
was previously reported as a weak inhibitor of -glucosidase, our 
data suggests that the use of a polar solvent (DMSO) in the bioassay 
conditions has produced inaccurate results, especially for low 
polarity compounds. Oleic acid showed higher activity than both 
palmitic acid and acarbose. These compounds exhibited a 
competitive type of inhibition against S. cerevisiae α-glucosidase. 
Therefore, this fatty acid-rich plant might also be an interesting 
alternative for reducing blood sugar level in people affected by DM. 
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Figure 6: Comparison between the interaction of Palmitic acid (a), Oleic acid (b) and acarbose (c) with a-glucosidase active site. 
 
 
Experimental 
 
General Experimental Procedures: NMR spectra were acquired on 
Jeol Eclipse 400 MHz spectrometer (referenced to H 7.26, C 77.0 for CDCl3). APCIHR-MS were acquired on a JEOL LC-mate mass spectrometer. The purification of the compounds was carried out on 
Agilent 1100 HPLC system equipped with a quaternary pump, a 
diode array detector, and a normal phase silica gel column 
(Phenomenex Luna, 4.6 mm × 100 mm, 5 μm) at a flow rate of 1 
mL/min. Column chromatography was used with silica gel 60 (70-
230 mesh, Merck). TLC (analytical) was performed on pre-coated 
silica gel 60 F254 plates (Merck). All solvents were HPLC grade 
and used without further purification.  
 
Plant material and extract preparation: B. pyramidatum 
(Acanthaceae) was collected in Santa Clara, Chiriquí, in the 
Republic of Panama. This plant was identified by Jorge Lezcano 
and was deposited to the Herbarium at the University of Panama. 
The aerial plant parts were dried at room temperature for a week 
and then were grounded for further study. This material (50.0 g) 
was extracted by maceration at room temperature with a mixture of 
CHCl3-MeOH (1:1). The solvent mixture was mixed with activated carbon (charcoal; 5 g) and stirred for 20 minutes at room 
temperature. The solution was filtered through celite in a Büchner 
funnel. The resulting solution was evaporated under reduced 
pressure to remove the solvent to leave a semi-solid paste (4.6 g). 
 
Chemical studies: The crude extract was subjected to bioassay-
guided fractionation in which the extract was re-suspended in a 
mixture of water-MeOH 70:30 and sequential partitions were made 
with Hexanes [Hex] (5×200 mL) and ethyl acetate [AcoEt] (5×200 
mL). Each obtained fraction, including the final hydromethanol 
fraction, was evaporated to dryness and then subjected to enzymatic 
assay. Hex fraction (active, 1.61 g) was fractionated by column 
chromatography on silica gel (35 g). The column was eluted with 
Hex, followed by a gradient of Hex:EtOAc (1:0→0:1) and finally 
with a gradient of EtOAc:MeOH (1:0→1:1). Altogether, 109 
fractions (25 ml each) were collected and combined according to 
their TLC profiles to yield nine primary fractions (FA to FI), which 
were re-evaluated against -glucosidase and the activity was 
presented in fraction FA [eluted with 100% Hex]. Fraction FA (0.31 
g) was further subjected to silica gel column chromatography and 
eluted with a gradient of Hex:EtOAc (1:0→0:1). This process led to 
six fractions (FA-1 to FA-6), which were also evaluated. Fraction 
FA-2 was eluted with Hex:EtOAc (9:1) to afford 3.1 mg of 
compound 1, which was the compound responsible for the activity. 
The other fractions were also evaluated but did not show an 
inhibitory effect in vitro against the enzyme -glucosidase. 
 
Alpha-glucosidase inhibitory assay: The -glucosidase inhibitory 
assay was performed according to Chan and collaborators [9a], with 
modifications [12a and b]. α-Glucosidase from baker’s yeast was 
purchased from Sigma Chemical Co. The inhibition was measured 
spectrophotometrically at pH 7.0 and 37°C employing 2 mM p-
nitrophenyl α-D-glucopyranoside (PNP-G) as a substrate and 32 
mU/mL of the enzyme, in 100 mM potassium phosphate buffer 
(enzyme stock). Acarbose was dissolved in phosphate buffer, and 
serial dilutions were prepared (in order to obtain the IC50) and employed as positive control. The absorbance (A) of 4-nitrophenol 
released by the hydrolysis of PNP-G was measured at 400 nm by 
Synergy HT Bio Tek microplate spectrophotometer. A 20 µL of 
acarbose, plant extract or isolated compound solution (in DMSO or 
Etanol) were incubated for 7 min with 150 µL of enzyme stock at 
37°C. After incubating, 150 µL of substrate was added and further 
incubated for 20 min at 37°C. All assays were performed in 96-well 
microplates (Greiner bio-one 655101) in triplicate. The activity of 
samples was calculated as a percentage in comparison to a control 
according to the following equation: 
 
Figure 5: Docking poses of compound 1 (a) and compound 2 (b). H-bond interactions are highlighted.  
(b)  (a)  
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 The concentration required to inhibit activity of the enzyme by 50% 
(IC50) was calculated by regression analysis [13].  
Kinetics of α-glucosidase inhibition: Fixed amounts of -
glucosidase were incubated with increasing concentrations of PNPG 
at 37C for 15 min, in the absence or presence of inhibitors 
(concentration equivalent to their IC50). Reactions were terminated, and absorption was measured and analyzed by Lineweaver–Burk 
plot. All the determinations were performed in triplicate. 
 
Statistical analysis: The data were expressed as the mean ± SD of 
three replicates. The analysis was performed using Excel 2013. 
One-way analysis of variance (ANOVA) and Tukey posttest were 
used to evaluate the possible differences among the means. p values 
≤ 0.05 were considered as significant differences. 
 
Docking Study: Ligands were constructed in Spartan’10 [14], and 
their geometry was optimized using MMFF force field. A protein-
ligand docking study was carried out based on the crystal structures 
for C- terminal domain of human intestinal α-glucosidase (PDB: 
3TOP) [15], which was retrieved from the Protein Data Bank [16]. 
Before docking, all of the solvent molecules and the co-crystallized 
ligand were removed. Molecular docking calculations were 
performed using Molegro Virtual Docker v. 6.0.1 [17]. A sphere of 
12 Å radius was centered in the binding site for searching.  
Experimental data indicates palmitic and oleic acids are competitive 
inhibitors; thus, the active site was chosen as the binding site. 
Protonation states and assignments of the charges on each protein 
were based on standard templates of the Molegro Virtual Docker 
program, and no other charges were necessary to set. Flexible 
ligand model was used in the docking and subsequent optimization 
scheme. Different orientations of the ligands were searched and 
ranked based on their energy scores. The RMSD threshold for 
multiple cluster poses was set to <1.00 Å. The docking algorithm 
was set to 5000 maximum iterations with a simplex evolution 
population size of 100 and a minimum of 50 runs for each ligand. 
After docking, some further scores were calculated including the 
binding affinity (MolDock Score) and re-ranking score (Rerank 
Score). The re-ranking score utilizes a more advanced scoring 
scheme than that used during docking and is often more useful for 
accurate ranking of the poses. Poses with lower score were selected 
for further analysis. To assess the efficacy of this procedure for 
finding low energy solutions, we docked the co-crystallized ligand 
(acarbose).  
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